Literature DB >> 24692689

The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model.

Gladiany Ramos1, Yaliz Loperena, Giovanni Ortiz, Fiorella Reyes, Ada Szeto, Jose Vera, Javier Velez, Jessica Morales, Deborah Morrero, Linnette Castillo, Surangani Dharmawardhane, Enrique Melendez, A Valance Washington.   

Abstract

BACKGROUND/AIM: Titanocene dichloride held great promise as a chemotherapeutic compound in pre-clinical studies. However, subsequent clinical trials revealed hepatoxicity and nephrotoxicity, which limited its use in clinical applications. Therefore, we used steroid pendant groups to improve the targeting of titanocene in MCF-7 breast cancer cells, and demonstrated a 10-fold lower effective dose compared to titanocene in in vitro assays. The aim of the present study was to test the efficacy of a titanocene functionalized with pregnenolone (Ti-Preg) in an in vivo breast cancer model.
MATERIALS AND METHODS: Xenografts from the MCF7 breast cancer cell line were implanted into athymic nu/nu mice to evaluate the potential of Ti-Preg as an anti-breast cancer agent.
RESULTS: Ti-Preg demonstrated significant inhibition of MCF-7 tumor growth when compared to vehicle and to titanocene controls.
CONCLUSION: Our findings demonstrate the potential of steroid pendent groups for targeting chemotherapeutics to steroid hormone-dependent cancer.

Entities:  

Keywords:  TLT-1; Titanocene; breast cancer; steroid pendant groups; titanocenyl-pregnenolone

Mesh:

Substances:

Year:  2014        PMID: 24692689      PMCID: PMC4053690     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

Review 1.  Disseminated intravascular coagulation.

Authors:  M Levi; H Ten Cate
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Titanocene dichloride--the first metallocene with cancerostatic activity.

Authors:  H Köpf; P Köpf-Maier
Journal:  Angew Chem Int Ed Engl       Date:  1979-06       Impact factor: 15.336

3.  Synthesis, Structure and Biological Activity of Amide-Functionalized Titanocenyls: Improving their Cytotoxic Properties.

Authors:  Li Ming Gao; Jaime Matta; Arnold L Rheingold; Enrique Meléndez
Journal:  J Organomet Chem       Date:  2009-12-15       Impact factor: 2.369

4.  The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment.

Authors:  James L Gattis; A Valance Washington; Maia M Chisholm; Laura Quigley; Agnieszka Szyk; Daniel W McVicar; Jacek Lubkowski
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

5.  Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.

Authors:  P Köpf-Maier; H Köpf
Journal:  Naturwissenschaften       Date:  1980-08

6.  Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.

Authors:  C V Christodoulou; D R Ferry; D W Fyfe; A Young; J Doran; T M Sheehan; A Eliopoulos; K Hale; J Baumgart; G Sass; D J Kerr
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

7.  Cytotoxic properties of titanocenyl amides on breast cancer cell line mcf-7.

Authors:  Li Ming Gao; Enrique Meléndez
Journal:  Met Based Drugs       Date:  2010-05-04

8.  Synthesis, Ti(IV) intake by apotransferrin and cytotoxic properties of functionalized titanocene dichlorides.

Authors:  Li Ming Gao; Ramón Hernández; Jaime Matta; Enrique Meléndez
Journal:  J Biol Inorg Chem       Date:  2007-06-14       Impact factor: 3.358

Review 9.  Titanium complexes in cancer treatment.

Authors:  Enrique Meléndez
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

10.  Anti-proliferative activity and mechanism of action of titanocene dichloride.

Authors:  C V Christodoulou; A G Eliopoulos; L S Young; L Hodgkins; D R Ferry; D J Kerr
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  1 in total

1.  Crystal structure of 16-ferrocenylmethyl-3β-hydroxy-estra-1,3,5(10)-trien-17-one: a potential chemotherapeutic drug.

Authors:  José A Carmona-Negrón; Mariola M Flores-Rivera; Zaibeth Díaz-Reyes; Curtis E Moore; Arnold L Rheigold; Enrique Meléndez
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.